International Assets Investment Management LLC Purchases New Shares in GoodRx Holdings, Inc. (NASDAQ:GDRX)

International Assets Investment Management LLC purchased a new stake in GoodRx Holdings, Inc. (NASDAQ:GDRX) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 17,186 shares of the company’s stock, valued at approximately $115,000.

A number of other institutional investors have also made changes to their positions in GDRX. Harbor Capital Advisors Inc. raised its holdings in shares of GoodRx by 22.7% in the third quarter. Harbor Capital Advisors Inc. now owns 14,995 shares of the company’s stock valued at $84,000 after buying an additional 2,771 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in shares of GoodRx by 7.5% in the third quarter. Bank of New York Mellon Corp now owns 189,560 shares of the company’s stock valued at $1,067,000 after buying an additional 13,235 shares during the last quarter. Mackenzie Financial Corp bought a new position in shares of GoodRx in the third quarter valued at about $68,000. Olympiad Research LP raised its holdings in GoodRx by 56.0% during the 3rd quarter. Olympiad Research LP now owns 50,184 shares of the company’s stock worth $283,000 after purchasing an additional 18,009 shares during the last quarter. Finally, Victory Capital Management Inc. bought a new stake in GoodRx during the 3rd quarter worth about $121,000. 63.77% of the stock is owned by institutional investors.

Analysts Set New Price Targets

GDRX has been the subject of several recent research reports. KeyCorp raised GoodRx from a “sector weight” rating to an “overweight” rating and set a $9.00 price objective for the company in a report on Wednesday, April 10th. Wells Fargo & Company upgraded GoodRx from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $7.50 to $10.00 in a research report on Monday, March 25th. UBS Group boosted their target price on GoodRx from $5.00 to $8.00 and gave the stock a “neutral” rating in a research report on Friday, March 1st. The Goldman Sachs Group boosted their price objective on GoodRx from $6.50 to $7.50 and gave the company a “neutral” rating in a research report on Friday, March 1st. Finally, Bank of America lowered GoodRx from a “buy” rating to an “underperform” rating and decreased their price objective for the company from $8.00 to $4.50 in a research report on Tuesday, January 2nd. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $8.78.

GoodRx Stock Performance

GDRX opened at $7.15 on Tuesday. The firm has a market cap of $2.82 billion, a P/E ratio of -357.32, a price-to-earnings-growth ratio of 3.94 and a beta of 1.42. GoodRx Holdings, Inc. has a 52-week low of $4.14 and a 52-week high of $9.37. The company has a debt-to-equity ratio of 0.85, a quick ratio of 7.12 and a current ratio of 7.12. The business’s fifty day moving average is $6.95 and its 200-day moving average is $6.29.

GoodRx (NASDAQ:GDRX) last released its earnings results on Thursday, February 29th. The company reported $0.02 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.02. The company had revenue of $196.64 million for the quarter, compared to analyst estimates of $195.59 million. GoodRx had a positive return on equity of 2.45% and a negative net margin of 1.18%. Sell-side analysts expect that GoodRx Holdings, Inc. will post 0.23 EPS for the current fiscal year.

GoodRx Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.